Lannett New York Listing Under Threat As FDA Says No On Advair
Flurry Of Announcements Also Sees Lannett Agree Sale Of Carmel Site
A strained balance sheet and share price has led the New York Stock Exchange to write to Lannett about its future listing, adding to its woes as the FDA confirmed it was not currently in a position to approve its partnered generic Advair Diskus asset.
